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Summary Sera from 31 HBsAg-positive Chinese patients with inoperable hepatocellular carcinoma (HCC)
were tested for hepatitis B virus DNA (HBV DNA) by means of dot hybridisation and Southern blot
technique. HBV DNA probes were prepared from human plasma. Eighteen of the patients were HBeAb-
positive, 12 were HBeAg-positive and one case had neither marker. Serial specimens were obtained from 16
cases over 5-42 weeks, while the patients were treated with recombinant leukocyte A interferon (rIFN-A) or
adriamycin. Seven patients (2 HBeAg-positive, 5 HBeAb-positive) were positive for HBV DNA. In two
patients HBV DNA and HBV DNA polymerase (DNAp) appeared in serum weeks after rIFN-A or
adriamycin treatment was started. In two other cases, HBV DNA that was initially present disappeared
during rIFN-A treatment. In a fifth patient HBV DNA persisting after adriamycin treatment diminished after
change of treatment to rIFN-A. With one possible exception the HBV DNA detectable by Southern blot
technique was composed chiefly of sequences 2.2-3.2kb size indicating the presence of unintegrated DNA
forms. DNAp activities were raised in the presence of HBV DNA in 4 patients. These findings show that
HBV replication can be activated or suppressed in advanced HCC. Treatment with rIFN-A may have been
effective in suppressing HBV DNA synthesis, but the number of cases studied was too small to arrive at a
definite conclusion on this point.
There is a causal relationship between hepatitis B
virus infection and hepatocellular carcinoma
(Beasley et al., 1981; Lai et al., 1984). Nonetheless,
HBV replication may be weak or absent, since
serum from patients with HCC contains low or
undetectable levels of HBV DNA (Lieberman et al.,
1983; Fowler et al., 1984; Song et al., 1984).
Interferon inhibits HBV replication in hepatitis
patients (Scullard et al., 1981; Thomas & Bassen-
dine, 1980; Omata et al., 1985), but its effect on
patients with HCC has so far not been reported.
This report deals with HBV DNA and DNAp in
HCC patients treated with rIFN-A or adriamycin
(Lai et al., 1984). By testing serial specimens
collected over weeks or months, we have been able
to show that free HBV DNA sequences may appear
intermittently in some patients during adriamycin
or rIFN-A treatment. In other patients, serum HBV
DNA disappeared during rIFN-A treatment.
Materials and methods
Preparation ofHBV DNA probesfrom plasma
A standard procedure (Weller et al., 1982) was
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modified with a DNAse digestion step in order to
eliminate human DNA. Plasma specimens rejected
by the blood bank because of HBsAg positivity
were used as the source of HBV DNA. Each
specimen (- 150ml) was centrifuged at 2000g (1 hr,
4°C). Six 25ml portions were layered over 10ml
30% sucrose cushions and centrifuged (70,000g,
17h, 4°C). The pellets were suspended in 2ml 0.1 M
sodium acetate-0.005 M Mg acetate, pH 5, and
40 il pancreatic DNAse (lmgml-1 in 0.15M
NaCl-50% glycerol) was added. After 20min at
37°C, 0.1 ml 0.2M EDTA, pH 7, was added and
the mixture was layered over 30ml 30% sucrose
and ultracentrifuged as before. (An optional [3H]-
labelling step was carried out: the pellet was dis-
solved in Nonidet P40-mercaptoethanol-Tris-saline
and 100I d buffer salts solution containing 10 uCi
[3H]dCTP (specific activity 20Cimmol-1), dATP,
dGTP and dTTP was added. After 2h at 37°C,
200 ul 0.2M EDTA was added; the mixture was
layered over 4.2ml 30% sucrose made up in Tris-
EDTA-mercaptoethanol-albumin-saline (Lin et al.,
1983) and centrifuged (190,OOOg, 4h, 4°C)). The
pellet was digested with proteinase K (1 mgml 1, in
1% SDS-0.05 M EDTA) at 37°C for 2h, and
extracted twice with phenol. Eight pg tRNA and
2vol ethanol were added per 100pl extract. After
2h at -20°C, nucleic acids were pelleted (9000g,
5min, 22°C), and washed with 70% ethanol; traces
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of ethanol were removed by drying under vacuum
at 220C. The HBV DNA (500-700ng) was
dissolved in 100p1 0.01 M Tris, pH 7.5.
HBV DNA was labelled with (32P)dCTP with the
aid of a nick translation kit (Amersham Inter-
national, UK). Typically, 10-15l1 of HBV DNA
solution was incubated with 120pCi (32P)dCTP
(specific activity >7000Cimmol-1) and 20p1
enzyme solution in a total volume of 100 pl for
3.5h at 15°C. The desired specific activity of about
2 x 109dpmpg- DNA was attained, as proven by
labelling of 60ng samples of human DNA under
identical conditions.
Dot hybridisation
The procedure outlined by Berninger et al. (1982)
was employed, in which extracts were prepared
from serum with the aid of proteinase K, and
applied to nitrocellulose or nylon membranes using
the 'Hybri-Dot' apparatus (Bethesda Research
Laboratories, Gaithersburg, MD, USA). Hybridisa-
tion to either HBV or human DNA probes was
carried out at 37°C for 16h in 0.9M NaCl-0.09M
sodium citrate, 0.01 M Tris, pH 7.9, 165pgml 1
bovine serum albumin, 80 pgml 1 salmon DNA,
0.8% sodium dodecyl sulfate and 50% deionised
formamide. With HBV DNA probe, these
conditions corresponded to an effective temperature
of Tm-290C, and permitted the formation of
hybrids with 79% or more base pairing. With
human DNA probes, the conditions corresponded
to Tm-240C and permitted formation of hybrids
with 83% or more base pairing. Both of these
conditions are fairly stringent (Howley et al., 1979).
Washing was carried out exactly according to
Berninger et al. (1982).
Radioautography was performed with Kodak
XRP-1 film and intensifying screens, at -70°C. By
nick-translating the HBV DNA with the highest
specific activity dCTP available, the dot hybridisa-
tion test was made more sensitive than the DNAp
assay (Lin et al., 1984). Twenty-six HBsAg-positive
specimens with DNAp activities of 0-94nUP1
were tested under standard conditions, with
exposure times of 20, 35 and 110h. Every specimen
with activity > 15nU1- I was positive on all 3
radioautograms. Of the 16 specimens with
<15 nU -1 activity, two were positive at 20h, five
were positive at 35 h and six were positive at 110 h.
Electrophoresis and Southern blotting
Electrophoresis was carried out in 0.9% agarose in
Tris acetate-EDTA-NaCl buffer for 2.5h at
5voltscm-1 (Helling et al., 1974). Blots were
prepared according to a standard procedure
(Maniatis et al., 1982) on to nitrocellulose or nylon
membranes. The samples analysed by Southern
blotting were either HBV DNA preparations that
were employed (in other experiments) for nick
translation, or serum extracts that were prepared by
the proteinase K method specified above and con-
centrated by means of ethanol precipitation. Hind
III digests of lambda DNA were co-electrophoresed
in side lanes. The conditions of hybridisation and
washing were identical to those employed in dot
hybridisation.
Other methods
Nucleic acids that were transferred to nylon
membranes ('Hybond-N', Amersham International)
were fixed by ultraviolet irradiation. Removal of
probe from the nylon sheets was accomplished by
two cycles of immersion in 0.4M NaOH (45°C,
30min) followed by incubation in a solution
composed of 0.2M Tris-HCl (pH 7.5), 0.1%
sodium dodecyl sulfate, 0.015M NaCl-0.0015M
sodium citrate (45°C, 30min). Complete removal of
radioactivity by this procedure was checked by
radioautography of the stripped membranes.
DNAp was assayed by the phosphonoformate
inhibition method; the cut-off point for serum
negative for HBsAg, HBsAb and HBcAb was
15nUI1 (Lin et al., 1984). The serological tests for
HBV markers are given in the same paper.
Patients
All patients with histologically proven HCC were
randomised to receive adriamycin or recombinant
leukocyte A interferon (rIFN-A) (Roche) when the
following criteria were fulfilled: (a) the HCCs were
inoperable as proven by hepatic arteriogram and/or
CT scan, (b) patient's age was less than 75yrs, (c)
the patients' performance status were over 60%
using the Karnovsky scale (i.e. they were able to
take care of most of their daily activities), (d) the
serum bilirubin levels were below lOOpmoll-', (e)
the patients had no cardiac complaints and normal
electrocardiograms and (f) informed consent was
obtained.
Patients on adriamycin were given an initial dose
of 60mgm 2 intra,venously. If this dose was well
tolerated, the dose was stepped up to 75mgm-2
once every three weeks. Patients receiving rIFN-A
were randomised on two regimes: (a) 9-
18 x 106IUm-2 intramuscularly daily and (b) 25-
50 x 106IUm-2 intramuscularly thrice weekly. The
dosages of adriamycin and rIFN-A were reduced
by one-third or half if serious side-effects developed
or if the bilirubin levels rose to above 100pmol -1.
Patients were switched over to the other drug if
there was progressive disease in spite of treatment
with one drug for a period of 12 weeks, or for aSERUM HBV DNA IN HEPATOCELLULAR CARCINOMA 69
minimum of 6 weeks depending on the clinical
status of the patient.
All patients were routinely tested for antibodies
to interferon by means of radioimmunoassays
carried out by Roche. Antibodies were detected in
two of the 31 patients, but not in the seven patients
with HBV DNA.
The general clinical status of the patients on the
different regimes were comparable, and the clinical
tolerance of the patients to rIFN-A, which has been
noted (Lai et al., 1984) will be detailed elsewhere
(Lai et al., in preparation). The HBV DNA
findings of the first 31 patients are presented below.
Results
Table I presents the findings together with the
treatment and serological data. Fifteen patients
were studied for 1-3 weeks (1-2 specimens per
case); six patients were followed for 5-10 weeks (3-
7 specimens per case) and 10 patients were followed
for 14-42 weeks (6-22 specimens per case). Seven
cases showed HBV DNA at some time during the
periods of observation. There was no statistically
significant association between the frequency of
HBV DNA positivity and either treatment. All 31
cases were HBsAg positive. Of the 12 HBeAg-
positive patients, only two were HBV DNA
positive. Five of the 18 HBeAb-positive cases were
HBV DNA positive.
The possibility that interference from traces of
human DNA in the HBV DNA probes could have
produced the findings was excluded. Figure 1 shows
Table I Serum HBV DNA, treatment and serological
data in 31 cases of hepatocellular carcinoma
HBV DNA
Positive Negative
Number of cases 7 24
Adriamycin 3 5
rIFN-A 3 15
Adriamycin followed by rIFN-A 1 2




HBeAg-negative, HBeAb-negative 0 1
that the procedure for isolation of HBV DNA (that
was detailed above) completely eliminated human
DNA. HBV DNA preparations (from which the
probes were made by nick translation) and plasma
or serum extracts were applied to nylon membranes
that were probed with HBV DNA, stripped of
radioactivity and reprobed with human DNA.
Comparison of radioautograms A and B revealed
that HBV DNA specimens (dots 1-3) showed no
trace of human DNA, whereas extracts of plasma
and serum specimens (dots 4-7) had various
amounts of human DNA, as would be expected in
human blood. HBV DNA specimens 1 and 2 were
employed in this study. Radioautogram C shows a
Southern blot of these specimens, prepared on a
nylon membrane that was subsequently stripped
and re-probed with human DNA (D). There was
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Figure 1 Absence of human DNA in HBV DNA specimens from which probes were prepared. A: membrane
probed with HBV DNA (5 million dpmml-1, exposure time 27h). B: the same membrane probed with human
DNA (10 milliondpmml-1, exposure time 47h). Dots 1-3: HBV DNA specimens 1-3; 4-7, extracts prepared
with proteinase K and phenol (see Methods) from blood specimens of different subjects. C: Southern blot of
HBV DNA specimens 1 and 2, and lambda DNA size markers, probed with a mixture of HBV DNA (5
million dpmml-1) and lambda DNA (106 dpmml-1), exposure time 40h. D: the same membrane probed with a
mixture of human DNA (5 million dpmml-1) and lamdba DNA (106 dpmml-1), exposure time 68h.70 H.J. LIN et al.
no reaction with human DNA at any position on
the blot. The validity of the hybridisation procedure
employed here was further proven by the fact that
34 out of 39 HBeAg-positive serum from subjects
without HCC gave positive results for HBV DNA.
Over 160 specimens were tested for HBV DNA
by means of dot hybridisation. Figure 2 shows
radioautograms that were typical of the results
obtained in this study. Control samples may be
considered first. The HBV DNA probes did not
react with human DNA (position IL) applied at
levels of 100 pg-100ng. Positive control samples
prepared from HBsAg-positive plasma with DNAp
activity reacted strongly (dots 2A and 4A). Only
serum from one patient, case 7, gave signals of
comparable intensity (2H). Figure 2 also illustrates
the variation in serum HBV levels with time. Dots
lC-lK and 2B-2G were serial specimens from case
3, starting from week 8 (after initiation of rIFN-A
treatment) and ending with a sample collected
during week 42, two days prior to his death. HBV
DNA appeared within only a short segmenit of this
period, at weeks 18-20 (11, 1J). Dots 3A-3K
illustrate the gradual appearance of HBV DNA in
case 4 over a period of 15 weeks; even at its highest
level the spots were relatively faint. Dots 4B-4G
show the dimunition of HBV DNA levels in case 5,
starting with a positive result and becoming
invisible toward the end of the series. These
observations were made on samples representing
75MI serum.
In order to obtain more intense signals for sizing
of the DNA by means of Southern blotting,
A B C D E F
samples representing about 200MI serum were
applied and exposure times of up to 150h were
used. Figure 3 shows blots of serial specimens from
3 patients treated with rIFN-A. Cases 1 and 2 were
similar in that the patients were initially positive for
HBV DNA, which then disappeared with during
the course of treatment. Case 3 was initially
negative for serum HBV DNA; however, after 4
months on rIFN-A he became positive for a
discrete period, and no HBV DNA was detected
thereafter until his death during week 42. rIFN-A
had been discontinued at week 30.
Figure 4 shows blots of serum samples in cases
treated with adriamycin. HBV DNA appeared
intermittently in case 4. It was first detected at
week 4 (with an elevated DNAp) and then from
week 7 onwards with increasing intensity.
Case 5 was treated with adriamycin for 24 weeks
and switched to rIFN-A at 27 weeks. Her serum
HBV DNA diminished over the ensuing weeks.
Case 6 shows the presence of HBV DNA after 12
weeks of adriamycin treatment. Case 7 was strongly
positive at weeks 0-4; he died during week 5.
The Southern blots showed that with the
exception of specimens from case 3, the sequences
hybridised to HBV DNA were present in fragments
approximately 2.2 to 3.2kbp in length. Similar size
distributions have been observed in DNA extracted
from purified HBV particles (Landers et al., 1977).
Moreover, similar size distributions were observed
in HBV DNA specimens that had been extracted
from DNAse-treated human plasma (Figure 1, C),
proving that such fragment lengths were associated





Figure 2 Radioautograms obtained in dot hybridisation tests. IL; human DNA. 2A and 4A: positive control
specimens. Dots IC-IK and 2B-2G are serial specimens from case 3 from week 8 (IC) to week 42 (2G); 11
and 1J are week 18 and week 20 specimens. Row 3 shows serial specimens from case 4 corresponding to those
in Figure 4; 3K, week 15 (DNAp, 41 nUI-1). Serial specimens from case 5 are shown in 4B-4G. Exposure
times were 86h for rows 1 and 2, and 46h for rows 3 and 4.SERUM HBV DNA IN HEPATOCELLULAR CARCINOMA
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r'igure 3 southern blots oi- serum extracts in patients treated with rIEN-A. Left to right, cases 1-3. 'nhe
positions of Hind III fragments of lambda DNA that were co-electrophoresed with the samples are shown at
the left of the blot. Weeks are counted from the day treatment was started. DNAp values on the same
specimen are shown at the top ofeach lane. X marks radioactive ink spots.








Figure 4 Southern blots of serum extracts from patients treated with adriamycin. Left to right, cases 4-7.
Case 5 had adriamycin up to week 24 and first received rIFN-A in week 27.
with HBV, not human DNA. Serum from case 3
(Figure 3, right) contained some of HBV DNA
sequences in the high molecular weight range. They
represented <10% of the hybrids formed.
Unfortunately further studies could not be carried
out to characterise these sequences, because of
insufficient serum. They could have been aggregates
of viral genome size DNA, or they could have been
viral sequences that had been integrated into host
DNA.
HBV DNAp was assayed in most of the
specimens. Serum from case 7 (Figure 4, right)
showed the highest levels of DNAp activity,
consistent with its high HBV DNA concentration.
Cases 3-5 had mildly raised DNAp activity in most
specimens that were positive for HBV DNA. There
was general agreement between the HBV DNA
tests and DNAp activities in these 4 patients,
proving that infective HBV was present in their
serum. The failure to find DNAp levels in cases 1
and 2 was not surprising, in view of the greater
sensitivity of the hybridisation technique.
Table II summarizes the data on serum trans-
aminases and HBeAg and HBeAb status. AST was
higher than ALT in these patients, but correlation
with the presence or absence of serum HBV DNA
was poor. HBeAg and HBeAb were followed
throughout the courses of treatment. Sero-
conversion from HBeAb to HBeAg was found only
in one patient (case 4, week 13) when his serum
HBV DNA was very strongly positive.
Discussion
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Table II Serum transaminases and HBeAg/HBeAb status in the HBV DNA-
positive cases
Case (sex) Week(s) HBV DNA ALT' AST' HBeAg HBeAb
1 (M) 0 + 123 255 +
7 - 64 268 ntb nt
9 - 47 301 - +
2 (M) 0 + 52 95 + -
6 + 82 290 nt nt
9 - 58 250 + -
12 - 97 307 + nt
3 (M) 9-11 - 39 63 - +
18-20 + nt nt - +
21 - 73 132 - +
31 - 7 65 - +
42 - 10 108 - +
4 (M) 0 - 76 78 - +
4 + nt 82 - +
9 + 72 117 - +
13 + 52 91 + nt
5 (F) 7 + nt nt + nt
12 + 2 18 nt nt
27 + 48 62 nt nt
31 - 151 150 + nt
6 (M) 1 + 44 122 - +
3 + 59 285 nt nt
7 (M) 0 + 80 150 - +
4 + 34 70 - +
aReference ranges (IUI1): ALT, 5-48 (M), 3-34 (F); AST,
(F); bnot tested.
open circles and as linear, partially single-stranded
forms (Landers et al., 1977; Ruiz-Opazo et al.,
1982; Elfassi et al., 1984). It has been proposed that
the bulk of serum HBV DNA that consists of
partially single-stranded molecules represent
defective viral particles while the supercoiled form
comes from infectious virus (Ruiz,-Opazo et al.,
1982). Supercoiled HBV DNA if present would not
have been detected because it constitutes only a
small fraction of serum HBV DNA; furthermore,
its position on the Southern blots would
correspond to that of a linear 2.3kbp DNA,
placing it within the smear of HBV DNA.
The overall frequency of serum HBV DNA
positivity in the present series of 31 cases as
compared to that in the series of 106 South African
blacks with HBV-related HCC was remarkably
similar, 7/31 or 23% vs. 20/106 (19%) (Song et al.,
1984). In our 7 positive cases 2 were HBeAg-
positive and 5 were HBeAb-positive. In the South
African study, the majority of the HBV DNA
positive cases were HBeAg-positive (14/20), 5 were
HBeAb positive and one was not tested for HBeAb.
11-35 (M), 8-32
HBeAb-positive HCC patients are, then, like
HBeAb-positive chronic hepatitis patients in that
they often show HBV DNA in serum (Lieberman et
al., 1983).
Comments on the effects of treatment are
necessarily tentative because of the small number of
cases. Treatment with adriamycin in cases 4-7 did
not prevent HBV replication. Since one effect of
adriamycin is to inhibit RNA-dependent DNA
synthesis (Bosman & Kessel, 1971) and HBV
replication most probably involves a reverse trans-
cription step, HBV DNA synthesis could have been
suppressed. However, this was not the case in the
four patients who had undergone 4-24 weeks treat-
ment with this antibiotic. The disappearance from
serum of HBV DNA in cases 1, 2 and 5 suggested
that rIFN-A was effective in suppressing HBV
DNA synthesis in HCC patients. Such an effect
would be consistent with its action in chronic
hepatitis patients. However, any effect of rIFN-A
could also be overridden, as shown by the course of
events in case 3. There was a burst of HBV
replication in this patient after 4 months on rIFN-SERUM HBV DNA IN HEPATOCELLULAR CARCINOMA 73
A. Serum HBV DNA and DNAp then fell to
undetectable levels and remained so even after
treatment was discontinued. Case 3 remains an
anomaly that emphasizes our incomplete under-
standing of the factors that activate (or suppress)
replication of HBV forms in HBsAg carriers. The
chief point gained from this study was the fluctu-
ation of serum HBV DNA in patients with HBV-
related liver cancer. Single point tests for serum
HBV DNA may be inadequate, given the changes
that we have recorded.
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